Pre-Submission Review for Clinical Trial Manuscripts: What Reviewers and Editors Check First
Clinical trial manuscripts face the toughest editorial scrutiny in academic publishing. Here is what editors and reviewers check first, why CONSORT 2025 changes the requirements, and how to prepare before submission.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Decision cue: Clinical trial manuscripts have the highest stakes in academic publishing. The APCs at top medical journals run $3,000 to $10,000. The desk rejection rates at NEJM, Lancet, and JAMA run 80 to 90%. And as of 2025, CONSORT has been updated for the first time in 15 years, meaning the reporting requirements are more demanding than what most authors are accustomed to. A pre-submission review that does not account for these specific requirements is not enough.
Check your clinical trial manuscript readiness in 60 seconds with the free scan, or read on for the full preparation framework.
Why clinical trial manuscripts need more preparation than other paper types
Clinical trial manuscripts face a unique combination of pressures:
Editorial scrutiny is highest. General and internal medicine journals (Lancet, BMJ, Annals of Internal Medicine) have the highest rejection rates of any field. Editors at these journals review clinical trial manuscripts differently from observational studies: they expect independent statistical review, complete CONSORT reporting, and registered protocols with pre-specified analysis plans.
Statistical reviewers are independent. At NEJM, JAMA, Lancet, and BMJ, clinical trial manuscripts go through independent statistical review in addition to scientific peer review. The statistical reviewer evaluates your analytical methods independently and may raise concerns your clinical reviewers did not identify. Many authors are not prepared for this dual-track review.
Reporting standards just changed. CONSORT 2025 was published in April 2025 in the Lancet, Nature Medicine, BMJ, and JAMA simultaneously. This is the first update to the CONSORT statement since 2010. Manuscripts prepared under the old CONSORT 2010 standard may be returned for revision at journals that have adopted the new guidelines.
Registration and protocol requirements are strict. Every major medical journal requires prospective trial registration before participant enrollment. Manuscripts describing unregistered trials are returned without review. The registration number must appear in the abstract.
What CONSORT 2025 changed
The updated CONSORT 2025 statement introduces several requirements that were not in the 2010 version:
New in CONSORT 2025 | What it requires | Why it matters for your submission |
|---|---|---|
Statistical analysis plans | Enhanced transparency about pre-specified vs post-hoc analyses | Journals now expect the SAP to be available or summarized. Publicly available SAPs with insufficient detail have been flagged as a credibility issue. |
Data and material sharing | Explicit requirements for data accessibility | "Data available upon request" is no longer sufficient. Specific data sharing plans must be stated. |
Patient and public involvement | Documentation of PPI at all trial stages | The Lancet and BMJ particularly value this. Missing PPI documentation is a new rejection trigger. |
Harms reporting | Clearer definitions of both systematic and non-systematic harms | Incomplete adverse event reporting is flagged more aggressively under CONSORT 2025. |
Participant flow | More detailed requirements for the flow diagram | The flow diagram must be more comprehensive than what many authors are accustomed to. |
The CONSORT 2025 Explanation and Elaboration document should be consulted alongside the main guideline. Simply completing the checklist items is not enough. Editors and reviewers now have more specific expectations for how each item is addressed.
What editors check in the first 5 minutes
Before a clinical trial manuscript reaches peer review, an editor makes a desk decision. At top medical journals, this happens within 1 to 2 weeks. The editor is asking:
Does the trial change clinical practice?
This is the threshold question at NEJM, Lancet, JAMA, and BMJ. A well-designed trial that confirms existing practice is less interesting than one that changes it. The abstract must state the clinical implication concretely, not speculatively.
Is the trial registered and does the registration match the manuscript?
Editors check the registration against the manuscript. If the primary endpoint in the published paper differs from the registered primary endpoint without explanation, this raises serious concerns about selective reporting. Any post-hoc changes to the analysis plan must be disclosed and justified.
Is the CONSORT checklist complete and specific?
A CONSORT checklist where every item says "see Methods" is not specific enough. Each item should reference a specific page, paragraph, or section. Editors can tell when the checklist was completed as an afterthought versus when it guided the manuscript preparation.
Does the statistical analysis survive 5 minutes of scrutiny?
Editors with statistical training (and at top journals, most have it) check for: sample size justification with power analysis, clearly stated primary and secondary outcomes, pre-specified analysis plan, appropriate handling of missing data, and honest discussion of multiplicity and subgroup analyses.
The clinical trial pre-submission checklist
Before submitting a clinical trial manuscript to any journal:
- the trial is registered in an approved registry (ClinicalTrials.gov, WHO ICTRP, etc.) with the number in the abstract
- the registered primary endpoint matches the manuscript's primary endpoint (or changes are explained)
- the CONSORT 2025 checklist is complete with specific page/section references
- the CONSORT flow diagram meets the updated 2025 requirements
- the statistical analysis plan is available or summarized in the methods
- sample size calculation is stated with power, effect size, and alpha
- primary and secondary outcomes are clearly distinguished
- missing data handling is described (intention-to-treat, per-protocol, sensitivity analyses)
- subgroup analyses are identified as pre-specified or post-hoc
- adverse events and harms are reported per CONSORT 2025 standards
- data sharing plan is specific (repository, timeline, access conditions)
- patient and public involvement is documented
- all authors have declared conflicts of interest
- ethics approval is stated with institution name and approval number
Where standard editing services fall short for clinical trials
Clinical trial manuscripts require a reviewer who understands:
- whether the statistical analysis plan is appropriate for the design
- whether the CONSORT 2025 requirements are met (not the 2010 requirements)
- whether the registered protocol matches the manuscript
- whether the subgroup analyses are credible or fishing expeditions
- whether the missing data approach is appropriate
Traditional editing services (Editage at $200, AJE at $289, Enago at $149 to $399) assign generic PhD holders who read the text and comment on structure. They do not verify protocol-manuscript consistency. They do not check whether CONSORT 2025 requirements are met. They do not evaluate whether the statistical approach is appropriate for the trial design.
The Manusights AI Diagnostic ($29) evaluates methodology, verifies citations against 500M+ live papers, and provides a structured assessment calibrated to your target journal. For clinical trial manuscripts targeting NEJM, Lancet, JAMA, or BMJ, the $29 diagnostic catches issues that a $200 editing review will miss because it was not designed to evaluate clinical trial-specific requirements.
For the highest-stakes trial manuscripts, Manusights Expert Review ($1,000 to $1,800) connects you with a reviewer who has published clinical trials in and reviewed for your target journal. A reviewer who has sat through independent statistical review at NEJM knows what those statistical reviewers look for. No editing service provides this.
The cost context
Clinical trial manuscripts have the highest cost of rejection:
- APCs at top medical journals: $3,000 to $10,000+ for open access
- grant reporting timelines: delayed publication can affect progress reports and renewals
- regulatory implications: some trials have regulatory documentation that depends on publication timing
- patient impact: delayed publication of clinical evidence delays changes in clinical practice
A $29 diagnostic or a $1,000 expert review is a small fraction of these costs. For clinical trials, the ROI calculation is the most favorable of any manuscript type.
Sources
On this page
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Final step
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan. See score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Need deeper scientific feedback? See Expert Review Options
Where to go next
Supporting reads
Conversion step
Find out if this manuscript is ready to submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.